(BRIEF) Merck, a leading science and generation company, announces a €14 million expansion of its M LabTM collaboration center in Shanghai, reinforcing its commitment to the biopharmaceutical industry in China. The expansion includes new facilities such as a Biological Applications Laboratory, Process Laboratory Development Training Center and Upstream Applications Laboratory, which offer complex functions tailored to biopharmaceutical and biological companies. In addition, Merck is consolidating its laboratories in Shanghai under the new Shanghai Technical Application and Testing Center, fostering collaboration and innovation across disciplines.
(PRESS RELEASE) DARMSTADT, March 26, 2024 — /EuropaWire/ — Merck, a leading science and generation company, has expanded its M LabTM collaboration center in Shanghai, the largest in its network of ten interconnected laboratories. The €14 million investment adds a new Biological Applications Lab, Process Development Training Center and Upstream Applications Lab to the existing M LabTM Collaboration Center in Shanghai.
“With the changing desires of the biopharmaceutical industry in China and the increasing focus on novel drug therapies, we are seeing increasing demand for procedural progression and skills progression programs in the region,” said Dr. Roy Wu, Chief Executive Officer of Life Sciences. Merck China Business Unit”. Our expansion of the M LabTM collaboration center in Shanghai will offer more capabilities and custom-designed solutions, helping biopharmaceutical and biologics corporations expand production and more productive practices that will save time, cost, and scale. time-to-market for life-saving therapies.
Opened in 2020 and strategically located in Pudong, in the middle of Shanghai’s biomedical park, the M LabTM collaboration center offers customizable responses tailored to China’s life sciences networks to help advance drug progression. It includes Procedure Progression and Pilot Scale Labs that supply non-GMP (Good Manufacturing Practice) lab area where pharmaceutical and biopharmaceutical brands can explore ideas, learn techniques, and work side-by-side with the company’s scientists and engineers to solve production and progression challenges for critical procedures. Customers can participate in product demonstrations, hands-on education, educational courses, and formal bioprocess experiences, and apply the most productive practices and new approaches to develop, optimize, and scale procedures.
With this expansion, Merck will offer more features to its consumers in China:
Biological Applications Laboratory: This suite of laboratories includes a general biology laboratory, a cell culture laboratory, and two biosafety level 2 (BSL-2) laboratories that provide capabilities such as mobile culture, adeno-associated virus (AAV) packaging, protein expression and purification, and immunoassays for biopharmaceutical and educational consumers in antibody development, production, and validation, pattern assays and immunoassay development.
Process Development Training Center: Includes two educational rooms, an initial lab, a post-lab and a pilot lab, offering complex answers and educational courses for biopharmaceutical companies, policymakers, regulatory bodies and agencies, universities, and other scholars with comprehensive knowledge. for upstream and downstream processes, such as mobile culture, bioreactor, clarification, chromatography, ultrafiltration, viral filtration, and sterile filtration.
Bottom-Up Applications Lab: With a BSL-2 lab and an analytical lab, this lab area provides technologies to support new modalities and the vaccine industry, from the mobile line to traditional mobile culture media, using mobile cultures and analytical methods. Platforms to help consumers improve their upstream processes, as well as the productivity and quality of their manufacturing.
Shanghai Technical Application and Testing Center: In an effort to foster collaboration, drive progress, and break down silos that can obstruct interdisciplinary advancements, the company is consolidating its existing labs in Shanghai under one name: Shanghai Technical Application and Testing Center. It indicates a strong commitment to collaboration, bringing consumers together along the price chain and making significant contributions to the clinical community. The center is home to 14 M LabTM Collaboration Center labs and several BioRelliance® Biotesting Center labs opened in 2022.
All Merck press releases are distributed by email at the time they are available on the Merck website. Visit www. merckgroup. com/subscribe to register online, replace your selection, or discontinue this service.
About Merck
Merck, a leading science and technology company, operates in the life sciences, healthcare, and electronics industries. Approximately 63,000 painters work every day to make a positive difference in the lives of millions of people by creating happier and more sustainable lifestyles. Whether it’s offering products that drive drug development and production, finding unique techniques to treat the most challenging diseases, or enabling artificial intelligence, the company is everywhere. In 2023, Merck generated sales of €21 billion in 65 countries.
Scientific exploration and guilty entrepreneurship have been key to Merck’s technological and clinical advancements. This is how Merck has thrived since its founding in 1668. The circle of founding family members remains the majority shareholder of the publicly traded company. Merck owns the international rights to Merck’s name and trademark. The only exceptions are the U. S. It is located in the U. S. and Canada, where Merck’s business lines operate, such as MilliporeSigma in life sciences, Merck Serono in healthcare, and Merck Electronics in electronics.
Media Contact:
SOURCE: Merck
MORE ON MERCK, ETC. : Leadership Changes Announced in Merck Family Board of Directors ElectionsMerck Launches Digital Center in Singapore to Drive Innovation in Semiconductors and HealthcareMerck KGaA Partners with Inspirna to Advance New Therapy for RAS Mutated Colorectal Cancer Erck Expands Biologics Testing Center in China to Support Local Biopharmaceutical InnovationMerck and Hengrui Register for Forces for Pioneering Cancer Therapies Worldwide Merck outlines resilience and growth strategy and aims to boost sales by fiscal 2024 Merck will showcase advancements in its oncology portfolio at ESMO 2023, highlighting key advances in cancer treatment. Set Revealing Potential Advances in RMSMERCK’s MAVENCLAD Treatment Shows Sustained Reduction in Plaque Damage in Sclerosis PatientsMerck Partners with UN for Major Educational Course for Family Caregivers on European Family Caregiver Day
EuropaWire (EW) is, in fact, the first pan-European press release distribution and press release distribution service for Europe and the European Union, which aims to consolidate Europe’s global voice of news agencies and media. Complex submission forms, flexible PR pricing and budgets, granular targeting, unlimited maximum success across countries, markets, verticals, sectors, audiences, languages, etc. , translation and localization for greater local PR impact, in-depth distribution. metrics and insights, adding measured PR success, readings, engagement, impact, etc. , with no limits on words, images, and multimedia to accompany your post, among other things. Your press releases will be among the most important press releases. and top companies, brands and vital establishments in Europe.
HOW DO I GET STARTED?